Table 2 R72P genotype frequency by clinical characteristics

From: The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

 

Non-del (5q)

Del (5q)

 

CC

CG

GG

CC

CG

GG

IPSS grouping (%), n

10 (32)

44.2 (142)

45.85 (147)

15.9 (28)

44.5 (73)

39.6 (65)

Low

9.4 (24)

46.1 (117)

44.5 (113)

16.9 (20)

48.3 (57)

34.7 (41)

High

11.9 (8)

37.3 (25)

50.7 (34)

13 (8)

34.8 (16)

52.2 (24)

P-value

 

0.421

  

0.119

 

Cytogenetics risk group (%), n

9.5 (34)

45.4 (162)

45.1 (161)

12.3 (38)

37.2 (115)

50.5 (156)

Iso-del(5q) or NA

9.8 (26)

45.7 (121)

44.5 (118)

10.8 (23)

37.6 (80)

51.6 (110)

Del(5q)+/1 Ab

9.6 (5)

44.2 (23)

46.2 (24)

9.5 (2)

52.4 (11)

38.1 (8)

Complex

7.5 (3)

45 (18)

47.5 (19)

17.3 (13)

32 (24)

50.7 (38)

P-value

 

0.992

  

0.325

 

WHO classification

9.8 (34)

45.5 (158)

44.7 (155)

12.6 (39)

38.2 (118)

49.2 (152)

Isolated del(5q)

0 (0)

0 (0)

0 (0)

8.9 (16)

36.3 (65)

54.7 (98)

RAEB-1

4 (2)

54 (27)

42 (21)

17.9 (5)

39.3 (11)

42.9 (12)

RAEB-2

18.8 (6)

28.1 (9)

53.1 (17)

11.8 (2)

52.9 (9)

35.3 (6)

RAEB-T

0 (0)

0 (0)

0 (0)

20 (1)

40 (2)

40 (2)

RA, RARS, RCMD, RCMD-RS

9.3 (23)

46.6 (115)

44.1 (109)

17.5 (11)

39.7 (25)

42.9 (27)

CMMLa

30 (3)

50 (5)

20 (2)

0 (0)

0 (0)

100 (2)

AML

0 (0)

0 (0)

100 (4)

26.7 (4)

40 (6)

33.3 (5)

P-value

 

0.041

  

0.372

 
  1. %, n
  2. Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; RA, refractory anemia; RAEB-1, refractory anemia with excess blasts-1; RARS, RA with ring sideroblasts; WHO, World Health Organization.
  3. aNon-proliferative MDS/MPN.
Back to article page